Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore Buys 19,610 Shares

Regulus Therapeutics Inc. (NASDAQ:RGLS) Director David Baltimore purchased 19,610 shares of Regulus Therapeutics stock in a transaction dated Thursday, January 30th. The stock was bought at an average cost of $1.06 per share, for a total transaction of $20,786.60. Following the completion of the purchase, the director now directly owns 22,169 shares in the company, valued at approximately $23,499.14. This trade represents a 766.31 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Regulus Therapeutics Stock Performance

Shares of RGLS remained flat at $1.00 during mid-day trading on Friday. 643,240 shares of the company traded hands, compared to its average volume of 590,682. The business has a fifty day moving average of $1.47 and a 200-day moving average of $1.55. Regulus Therapeutics Inc. has a twelve month low of $0.83 and a twelve month high of $3.79. The company has a market cap of $65.50 million, a PE ratio of -0.93 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Research analysts forecast that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Hedge Funds Weigh In On Regulus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Creative Planning acquired a new stake in Regulus Therapeutics in the third quarter worth about $26,000. SG Americas Securities LLC acquired a new position in shares of Regulus Therapeutics in the third quarter valued at $33,000. Jane Street Group LLC acquired a new position in Regulus Therapeutics during the third quarter worth $46,000. JPMorgan Chase & Co. boosted its holdings in Regulus Therapeutics by 193.4% in the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 52,059 shares during the last quarter. Finally, Barclays PLC raised its position in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 62,549 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.